Compare Bio-Rad Laboratories, Inc. Class A Common Stock (BIO) vs iShares S&P GSCI Commodity-Indexed Trust ETF (GSG) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Bio-Rad Laboratories, Inc. Class A Common Stock vs iShares S&P GSCI Commodity-Indexed Trust ETF — how do they compare? Bio-Rad Laboratories, Inc. Class A Common Stock trades at $360.3 (market cap $9.43B), while iShares S&P GSCI Commodity-Indexed Trust ETF trades at $32.6. The key difference: Bio-Rad Laboratories, Inc. Class A Common Stock is trading nearer its 52-week high, iShares S&P GSCI Commodity-Indexed Trust ETF nearer its low. Which is the better fit depends on your goals.
| BIO | GSG | |
|---|---|---|
Market Cap | $9.43B | — |
Sector | Health | Commodities - Metals/Agriculture |
52-Week High | $356.25 | $34.77 |
52-Week Low | $241.71 | $22.06 |
Enterprise Value | $9.18B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Bio-Rad Laboratories (BIO) trades at $357.58, up 0.86% today, near its 52-week high. The stock shows a bullish technical trend with strong moving average signals, though oscillators indicate overbought conditions. Fundamentally, the company reported a Q2 2026 earnings beat with EPS of $2.62 versus $1.75 expected, and net income for 2025 reached $759.9 million, a significant recovery from prior years. Analyst sentiment is positive with a consensus buy rating and a $350 price target, though the P/E ratio of 43.39 suggests a premium valuation.
The outlook for BIO is cautiously optimistic, driven by earnings momentum and improving cash flow, but risks include high valuation, competitive pressures in life sciences, and reliance on academic research markets. Upside potential exists if international revenue trends strengthen, but investors should monitor margin sustainability and debt levels, which have improved but remain a focus.
GSG trades at $32.65, up 1.02% today, with a bearish technical signal driven by moving averages. Recent news highlights its energy-centric commodity exposure, which fueled strong H1 2026 performance but faces volatility risks. Financial ratios are unavailable, limiting fundamental clarity.
Outlook is cautious due to sector volatility and geopolitical risks, with a recent downgrade to Hold. Opportunities lie in broad commodity exposure, but investors should weigh energy price swings and lack of current financial data against potential gains.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Bio-Rad Laboratories, Inc. Class A Common Stock
Bio-Rad Laboratories, headquartered in Hercules, California, develops, manufactures, and markets products and solutions for the clinical diagnostics and life sciences markets. In diagnostics (53% of sales), Bio-Rad manufactures, sells, and supports test systems and specialized quality controls for clinical laboratories. In life sciences (47% of sales), the firm develops and manufactures a range of instruments and reagents used in research, biopharmaceutical production, and food testing. The company is geographically diverse, with major markets in the Americas (42% of 2021 sales), Europe and Africa (33%), and Asia-Pacific (25%). Bio-Rad owns 37% of Sartorius AG, a laboratory and biopharmaceutical supplier.
Read more on BIO →About iShares S&P GSCI Commodity-Indexed Trust ETF
GSG is a diversified commodity ETF that tracks the S&P GSCI Total Return Index. It provides exposure to a broad basket of futures, including energy, metals, and agriculture, with a significant weighting toward the energy sector.
Read more on GSG →
